



# THC (1.BB.950): sc-73153

## BACKGROUND

Tetrahydrocannabinol (THC) is the main psychoactive substance found in the *Cannabis* plant. The most likely function of this compound in *Cannabis* is to protect the plant from herbivores or pathogens. THC also has UV-B absorption properties at about 280-315 nm, thus protecting the plant from harmful radiation. The pharmacological actions of THC are caused by its binding to the cannabinoid receptor CB1 in the brain, resulting in analgesic effects. Other effects of THC include relaxation, euphoria, disorientation, fatigue, appetite stimulation and an alteration of visual, auditory and olfactory senses. Research has shown the possibility of a beneficial role for THC in diseases such as multiple sclerosis, Parkinson's, cancer and Alzheimer's, though its status as an illegal drug in the United States makes research difficult.

## REFERENCES

1. Nilsson, I.M., Agurell, S., Nilsson, J.L., Ohlsson, A., Sandberg, F. and Wahlqvist, M. 1970.  $\delta$ -1-tetrahydrocannabinol: structure of a major metabolite. *Science* 168: 1228-1229.
2. Petro, D.J. and Ellenberger, C., Jr. 1981. Treatment of human spasticity with  $\delta$ -9-tetrahydrocannabinol. *J. Clin. Pharmacol.* 21: 413S-416S.
3. Moss, D.E., McMaster, S.B. and Rogers, J. 1981. Tetrahydrocannabinol potentiates reserpine-induced hypokinesia. *Pharmacol. Biochem. Behav.* 15: 779-783.
4. Clifford, D.B. 1983. Tetrahydrocannabinol for tremor in multiple sclerosis. *Ann. Neurol.* 13: 669-671.
5. Voth, E.A. and Schwartz, R.H. 1997. Medicinal applications of  $\delta$ -9-tetrahydrocannabinol and marijuana. *Ann. Intern. Med.* 126: 791-798.
6. Graceffo, T.J. and Robinson, J.K. 1998.  $\delta$ -9-tetrahydrocannabinol (THC) fails to stimulate consumption of a highly palatable food in the rat. *Life Sci.* 62: 85-88.
7. Carlini, E.A. 2004. The good and the bad effects of (-) trans- $\delta$ -9-tetrahydrocannabinol ( $\delta$ -9-THC) on humans. *Toxicol.* 44: 461-467.
8. Walther, S., Mahlberg, R., Eichmann, U. and Kunz, D. 2006.  $\delta$ -9-tetrahydrocannabinol for nighttime agitation in severe dementia. *Psychopharmacology* 185: 524-528.
9. Roberts, J.D., Gennings, C. and Shih, M. 2006. Synergistic affective analgesic interaction between  $\delta$ -9-tetrahydrocannabinol and morphine. *Eur. J. Pharmacol.* 530: 54-58.

## SOURCE

THC (1.BB.950) is a mouse monoclonal antibody raised against 8-THC.

## STORAGE

Store at 4° C, **\*\*DO NOT FREEZE\*\***. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.

## PRODUCT

Each vial contains 100  $\mu$ g IgG<sub>1</sub> in 1.0 ml PBS with < 0.1% sodium azide and 0.1% gelatin.

## APPLICATIONS

THC (1.BB.950) is recommended for detection of THC (Cannabinoids) and metabolites by solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with opiates, cocaine metabolite, amphetamines and Phencyclidine.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.